Abstract
Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bonetargeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.
Keywords: Prostate cancer, bone, metastasis, osteolytic, osteoblastic, bisphosphonate, RANK ligand, endothelin, TGF-beta
Anti-Cancer Agents in Medicinal Chemistry
Title: Agents Targeting Prostate Cancer Bone Metastasis
Volume: 9 Issue: 10
Author(s): Khalid S. Mohammad, Pierrick G. Fournier, Theresa A. Guise and John M. Chirgwin
Affiliation:
Keywords: Prostate cancer, bone, metastasis, osteolytic, osteoblastic, bisphosphonate, RANK ligand, endothelin, TGF-beta
Abstract: Bone is the most common site for metastasis of advanced prostate cancers. Once housed in the skeleton, tumors are incurable and cause protracted morbidity, and bone metastases may contribute to mortality through unknown mechanisms. Bone provides a unique microenvironment whose local interactions with tumor cells offer novel targets for therapeutic interventions. Many standard cancer treatments cause bone loss, which may aggravate skeletal metastases, although this is preventable with approved agents. Improved bonetargeted treatments can decrease the serious skeletal morbidities associated with metastatic prostate cancer and may in the future improve overall survival. The development of such treatments requires preclinical evaluation in animal models of prostate cancer growth in bone.
Export Options
About this article
Cite this article as:
Mohammad S. Khalid, Fournier G. Pierrick, Guise A. Theresa and Chirgwin M. John, Agents Targeting Prostate Cancer Bone Metastasis, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/187152009789735008
DOI https://dx.doi.org/10.2174/187152009789735008 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contribution of Poly(Amino Acids) to Advances in Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology MicroRNA-21 as a Novel Therapeutic Target
Current Cancer Therapy Reviews The Male Peripubertal Phase as a Developmental Window for Reproductive Toxicology Studies
Current Pharmaceutical Design Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Preface
Current Medical Imaging Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Current Medicinal Chemistry The Advancement of Human Serum Albumin-Based Molecular Probes for Molecular Imaging
Current Pharmaceutical Design Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design 5-Lipoxygenase: A Promising Drug Target Against Inflammatory Diseases-Biochemical and Pharmacological Regulation
Current Drug Targets Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Vitamin D Receptor is a Novel Drug Target for Ovarian Cancer Treatment
Current Cancer Drug Targets Probiotics as a Tool to Biosynthesize Metallic Nanoparticles: Research Reports and Patents Survey
Recent Patents on Drug Delivery & Formulation New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Transforming Growth Factor Beta in Pancreatic Cancer
Current Pharmaceutical Biotechnology Computational Protein Design: A Novel Path to Future Protein Drugs
Current Pharmaceutical Design Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design